Neuroendocrine neoplasm of the gallbladder: Clinical features, surgical efficacy, and prognosis.
adenocarcinoma
gallbladder
neuroendocrine neoplasm
prognosis
surgery
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
06
03
2023
received:
14
12
2022
accepted:
12
03
2023
medline:
7
6
2023
pubmed:
24
3
2023
entrez:
23
3
2023
Statut:
ppublish
Résumé
Neuroendocrine neoplasm (NEN) of the gallbladder is rare. It is usually asymptomatic and occurs in older adults. Its clinicopathological characteristics remain controversial, and the diagnosis and treatment strategies are usually based on models of adenocarcinoma. The present study aimed to investigate the clinical characteristics and prognosis of gallbladder NEN. The data of patients with gallbladder NEN admitted to Peking Union Medical College Hospital was reviewed, and a database was established for retrospective analysis. Clinicopathological features were analyzed descriptively and the prognosis was studied according to different factors. The Kaplan-Meier curve was used to describe the cumulative survival rate. In total, 22 patients with gallbladder NEN were included in this study. There were 10 male (45.5%) and 12 female (54.5%) patients with a median age of onset of NEN at 57.5 (49.0, 62.3) years. Abdominal discomfort was the most common symptom. Twenty patients (90.9%) underwent surgery, and two patients (9.1%) with unresectable lesions underwent a biopsy. Twenty-one patients were followed up. The 1-, 2-, and 3-year cumulative overall survival rates of all patients and patients with resectable lesions were 65.9%, 54.9%, and 48.1%, and 72.9%, 60.7%, and 53.1%, respectively. Patients with resectable lesions had a better cumulative overall survival rate than those who with unresectable lesions (p < 0.001). Gallbladder NEN is more common in the elderly and has a slight female predominance. The most common symptom is abdominal discomfort. Surgery is the first choice of treatment for this rare disease. The prognosis of gallbladder NEN is generally poor. Patients with resectable lesions have a better prognosis.
Sections du résumé
BACKGROUND
Neuroendocrine neoplasm (NEN) of the gallbladder is rare. It is usually asymptomatic and occurs in older adults. Its clinicopathological characteristics remain controversial, and the diagnosis and treatment strategies are usually based on models of adenocarcinoma. The present study aimed to investigate the clinical characteristics and prognosis of gallbladder NEN.
METHODS
The data of patients with gallbladder NEN admitted to Peking Union Medical College Hospital was reviewed, and a database was established for retrospective analysis. Clinicopathological features were analyzed descriptively and the prognosis was studied according to different factors. The Kaplan-Meier curve was used to describe the cumulative survival rate.
RESULTS
In total, 22 patients with gallbladder NEN were included in this study. There were 10 male (45.5%) and 12 female (54.5%) patients with a median age of onset of NEN at 57.5 (49.0, 62.3) years. Abdominal discomfort was the most common symptom. Twenty patients (90.9%) underwent surgery, and two patients (9.1%) with unresectable lesions underwent a biopsy. Twenty-one patients were followed up. The 1-, 2-, and 3-year cumulative overall survival rates of all patients and patients with resectable lesions were 65.9%, 54.9%, and 48.1%, and 72.9%, 60.7%, and 53.1%, respectively. Patients with resectable lesions had a better cumulative overall survival rate than those who with unresectable lesions (p < 0.001).
CONCLUSION
Gallbladder NEN is more common in the elderly and has a slight female predominance. The most common symptom is abdominal discomfort. Surgery is the first choice of treatment for this rare disease. The prognosis of gallbladder NEN is generally poor. Patients with resectable lesions have a better prognosis.
Identifiants
pubmed: 36952352
doi: 10.1002/cam4.5846
pmc: PMC10242308
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11344-11350Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Acta Gastroenterol Belg. 2019 Jul-Sep;82(3):433-436
pubmed: 31566333
World J Gastroenterol. 2020 Feb 14;26(6):686-695
pubmed: 32103876
Endocr Connect. 2019 Sep;8(9):1273-1281
pubmed: 31398710
J Dig Dis. 2022 Mar;23(3):166-173
pubmed: 35187836
Am J Surg Pathol. 2020 Oct;44(10):1308-1321
pubmed: 32739935
Cureus. 2019 Sep 5;11(9):e5571
pubmed: 31695990
Front Oncol. 2021 Nov 18;11:770156
pubmed: 34869003
Ann Surg Oncol. 2019 Oct;26(11):3577-3585
pubmed: 31102094
Orphanet J Rare Dis. 2019 Nov 21;14(1):266
pubmed: 31752927
Cancer Med. 2023 May;12(10):11344-11350
pubmed: 36952352
Clin Endosc. 2017 Nov;50(6):520-529
pubmed: 29207862
Gastrointest Tumors. 2021 Nov 18;9(1):5-11
pubmed: 35528747
Clin J Gastroenterol. 2019 Feb;12(1):38-45
pubmed: 30003469
Langenbecks Arch Surg. 2022 Feb;407(1):197-206
pubmed: 34236488
Case Rep Oncol. 2021 Mar 11;14(1):411-417
pubmed: 33776736
Cancer Med. 2022 Feb;11(3):641-653
pubmed: 34841738
J Gastrointest Cancer. 2019 Jun;50(2):298-303
pubmed: 29435905
Dig Surg. 2021;38(1):30-37
pubmed: 32570243
Front Oncol. 2021 Jul 19;11:654439
pubmed: 34350109
Cureus. 2020 Mar 31;12(3):e7487
pubmed: 32368420
J Gastrointest Cancer. 2015 Dec;46(4):356-64
pubmed: 26208508
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8218-26
pubmed: 26339390
Gastroenterology Res. 2020 Dec;13(6):269-278
pubmed: 33447306
Pancreas. 2020 Feb;49(2):e19-e20
pubmed: 32049953
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572940
Eur Radiol. 2020 May;30(5):2890-2901
pubmed: 32025835
Cancer Manag Res. 2020 Feb 26;12:1437-1446
pubmed: 32161496
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur Radiol. 2017 Feb;27(2):507-517
pubmed: 27225621
Abdom Radiol (NY). 2021 Jun;46(6):2474-2489
pubmed: 33386907
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593